European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
16 Jun

European equities traded in the US as American depositary receipts were trending higher late Monday morning, rising 0.60% to 1,497.18 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and DBV Technologies (DBVT), which rose 5.2% and 4.7% respectively. They were followed by telecommunications operator Telefonica (TEF) and Spanish lender Banco Santander (SAN), which were up 4.2% and 3.7% respectively.

The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and biotech firm Evaxion (EVAX), which fell 2.8% and 2.3% respectively. They were followed by biopharmaceutical company argenx (ARGX) and semiconductor company Sequans Communications (SQNS), which were down 2.1% and 1.8% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which advanced 19% and 5.1% respectively. They were followed by cruise line operator Carnival (CUK) and telecommunications operator Vodafone Group (VOD), which increased 5% and 3.5% respectively.

The decliners from the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Akari Therapeutics (AKTX), which dropped 2.8% and 2.5% respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which were off 2% and 1.9% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10